MOLOGNI LUCA
- U08, Piano: 4, Stanza: LABORATORIO 4.10
- U08, Piano: 4, Stanza: 4043
Pubblicazioni
Zapata Dongo, R., Fontana, D., Mologni, L., Faya Castillo, J., Infante Varillas, S. (2025). Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer. PLOS ONE, 20(1) [10.1371/journal.pone.0308747]. Dettaglio
Destro, L., Crippa, V., Gabbia, D., Roverso, M., Bogialli, S., Zardi, P., et al. (2025). Discovery of selective, metabolically stable pyrazole-based FLT3 inhibitors for the treatment of acute myeloid leukemia. RSC MEDICINAL CHEMISTRY, 16(4), 1766-1780 [10.1039/d4md00956h]. Dettaglio
Introvigne, M., Destro, L., Mologni, L., Crippa, V., Zardi, P., Fini, F., et al. (2025). α-Triazolylboronic Acids: A Novel Scaffold to Target FLT3 in AML. CHEMMEDCHEM, 20(1) [10.1002/cmdc.202400622]. Dettaglio
Zapata Dongo, R., Fontana, D., Mologni, L., Faya Castillo, J., Infante, V. (2025). Inhibition of the anti-apoptotic protein BCL2 in EML4-ALK cell models as a second proposed therapeutic target for non-small cell lung cancer. Intervento presentato a: Barcelona BioMed Conferences. AI in Drug Discovery and Biomedicine, Barcelona, Spain. Dettaglio
Civettini, I., Zappaterra, A., Corti, P., Messina, A., Aroldi, A., Biondi, A., et al. (2025). Hb Monza: A novel extensive HBB duplication with preserved α-β subunit interaction and unstable hemoglobin phenotype. MED, 6(4) [10.1016/j.medj.2024.11.007]. Dettaglio